RESEARCH TRIANGLE PARK, N.C. & ZURICH, SWITZERLAND – May 20, 2010 – Quintiles and Nycomed today announced an agreement under which the privately-held Swiss pharmaceutical company has transferred a U.K.-based Healthcare Solutions Team to Quintiles. This agreement further strengthens Quintiles’ market access capabilities and allows Nycomed to protect the employment of a high-performing group.
The transfer follows Nycomed’s decision to out-license a product to another pharmaceutical company in the U.K. During the transition period, the continued support, motivation and flexibility of the team remained crucial to commercial success. After the team’s transfer to Quintiles, it was contracted back to Nycomed to complete the work.
Melissa Thomas, Nycomed’s U.K. Managing Director, said: “In transferring the team to Quintiles and contracting it back, we created a real win-win-situation. The team has continued employment in an exciting new healthcare model and will be exposed to new opportunities through global industry leader Quintiles; whereas Nycomed continues to have access to their expertise.”
Team members have significant experience in the pharmaceutical industry and extensive interaction with the U.K. National Health Service (NHS). Familiarity with this critical stakeholder group will benefit Quintiles’ customers, as they seek to accelerate timelines, increase productivity, overcome complexity and demonstrate value. Achieving these objectives is an essential element in navigating the New Health – the complex challenges and opportunities faced by the bio pharmaceutical industry.
Following the initial product promotion, Quintiles will use the team’s market access expertise to support customers throughout the U.K. In addition, the team will promote Health Management Services directly to the NHS, in a unique effort to elevate the value of patient-centric services to payers.
Quintiles’ Chris Pepler, U.K. Managing Director Commercial, said: “Our goal is to serve as an ally for our customers to help ensure their products reach their full market potential. With bolstered market access capabilities, our customers can rely on Quintiles to help shift the critical conversation about a drug from cost to value among regulators, payers, providers and patients. We’re pleased to welcome the newest members of our market access team in the U.K.”
Quintiles is the only fully integrated bio pharmaceutical services company offering clinical, commercial, consulting and capital solutions worldwide. The Quintiles network of more than 20,000 engaged professionals in 60 countries works with an unwavering commitment to patients, safety and ethics. Quintiles helps bio pharmaceutical companies navigate risk and seize opportunities in an environment where change is constant. For more information, please visit www.quintiles.com.
Nycomed is a privately owned global pharmaceutical company with a differentiated portfolio focused on branded medicines in gastroenterology, respiratory and inflammatory diseases, pain, osteoporosis and tissue management. An extensive range of OTC products completes the portfolio. Its R&D is structured around partnerships and in-licensing is a cornerstone of the company's growth strategy. Nycomed employs 12,000 associates worldwide, and its products are available in more than 100 countries. It has strong platforms in Europe and in fast-growing markets such as Russia/CIS and Latin America. While the US and Japan are commercialised through best-in-class partners, Nycomed plans to further strengthen its own position in key Asian markets. Headquartered in Zurich, Switzerland, the company generated total sales of €3.2 billion in 2009 and an adjusted EBITDA of €1.1 billion. For more information visit www.nycomed.com